Loading
Ovarian Cancer Diagnosis and Treatment · Journal article
Cancers · August 14, 2026
A consensus or society position rather than new primary data.
This is a narrative review of therapeutic strategies for epithelial ovarian cancer, ranging from established approaches (PARP inhibitors, antiangiogenic agents, selected antibody–drug conjugates) with clinical maturity to experimental modalities (CAR-T, CRISPR/Cas9, gene therapies) remaining predominantly preclinical or early clinical. The authors identify chemoresistance, molecular heterogeneity, and immunosuppression as major barriers and call for biomarker-guided selection and rational sequencing to overcome treatment resistance.
Narrative literature review. Literature addressing epithelial ovarian cancer, with focus on chemoresistant and advanced-stage disease. Intervention: Multiple emerging therapeutic strategies: PARP inhibitors, antiangiogenic agents, antibody–drug conjugates, pathway inhibitors, immune checkpoint inhibitors, cancer vaccines, adoptive cell therapies, metabolic and epigenetic modulators, CA….
5-year survival in advanced-stage epithelial ovarian cancer is approximately 29% Most patients relapse within 2 years despite cytoreductive surgery and platinum–taxane-based chemotherapy PARP inhibitors, antiangiogenic agents, selected antibody–drug conjugates, MAPK-directed therapy in low-grade serous ovarian cancer, and HIPEC in selected settings have the strongest clinical support
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that PARP inhibitors, antiangiogenic agents, and selected antibody–drug conjugates have established clinical support and represent the standard approaches to overcome resistance; conversely, most immune, metabolic, adoptive cell, and gene-therapy strategies remain experimental and should be pursued within clinical trials or selected protocols with biomarker guidance.
A narrative review synthesizing preclinical and clinical evidence across multiple therapeutic modalities for ovarian cancer, identifying mature strategies (PARP inhibitors, antiangiogenic agents) and early-stage approaches, intended to guide therapeutic selection and future research directions.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that PARP inhibitors, antiangiogenic agents, and selected antibody–drug conjugates have established clinical support and represent the standard approaches to overcome resistance; conversely, most immune, metabolic, adoptive cell, and gene-therapy strategies remain experimental and should be pursued within clinical trials or selected protocols with biomarker guidance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: Epithelial ovarian cancer (EOC) remains a gynecologic malignancy with a poor prognosis, with a 5-year survival of approximately 29% in advanced-stage disease. Despite cytoreductive surgery and platinum- and taxane-based chemotherapy, most patients relapse within 2 years. Major therapeutic barriers include chemoresistance, molecular heterogeneity, and an immunosuppressive peritoneal microenvironment. This review summarizes emerging therapeutic strategies for EOC, their mechanisms of action, and their potential to overcome treatment resistance. Methods: PubMed/MEDLINE was searched for preclinical studies, phase I–III clinical trials, systematic reviews, and meta-analyses addressing novel ovarian cancer therapies and resistance mechanisms. Results: The review covers molecularly targeted therapies, immunotherapies, metabolic and epigenetic approaches, cellular and gene therapies, targeted drug-delivery systems, and locoregional and physical modalities. Strategies include PARP inhibitors, antiangiogenic agents, antibody–drug conjugates, pathway inhibitors, immune checkpoint inhibitors, cancer vaccines, adoptive cell therapies, metabolic and epigenetic modulators, CAR-T, CAR-NK, CRISPR/Cas9, HIPEC, PIPAC, ablation, photodynamic therapy, and sonodynamic therapy. Conclusions: The clinical maturity of these approaches varies substantially. PARP inhibitors, antiangiogenic agents, selected antibody–drug conjugates, MAPK-directed therapy in LGSOC, and HIPEC in selected settings have the strongest clinical support. Most immune combinations, metabolic and epigenetic therapies, adoptive cell therapies, gene-editing approaches, and novel delivery or physical modalities remain early clinical or predominantly preclinical. Progress will depend on biomarker-guided patient selection, reassessment of evolving resistance mechanisms, and rational treatment sequencing and combinations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.